Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Shares of Grail collapsed more than 50% in a single session despite the company reporting a narrower-than-expected fourth-quarter loss and reaffirming its 2026 revenue outlook of 22%–32% growth.</li><li>The trigger was not the income statement, but the top-line results from its 142,000-patient U.K. NHS-Galleri randomized trial.</li><li>While the Galleri multi-cancer early detection test demonstrated a greater than 20% reduction in Stage IV cancers in later screening rounds and a fourfold increase in overall cancer detection compared with standard of care, the study failed to meet its primary endpoint of a statistically significant reduction in combined Stage III and IV cancers.</li></ul>

Shares of Grail collapsed more than 50% in a single session despite the company reporting a narrower-than-expected fourth-quarter loss and reaffirming its 2026 revenue outlook of 22%–32% growth.The trigger was not the income statement, but the top-line results from its 142,000-patient U.K. NHS-Galleri randomized trial.While the Galleri multi-cancer early detection test demonstrated a greater than 20% reduction in Stage IV cancers in later screening rounds and a fourfold increase in overall cancer detection compared with standard of care, the study failed to meet its primary endpoint of a statistically significant reduction in combined Stage III and IV cancers.

Grail Stock Crashes 50% After Trial Miss—Is The Cancer Bet Broken?

GRAIL

Grail Stock Crashes 50% After Trial Miss—Is The Cancer Bet Broken?